CN103520260B - 一种治疗冠心病心绞痛的药物组合及制备方法 - Google Patents
一种治疗冠心病心绞痛的药物组合及制备方法 Download PDFInfo
- Publication number
- CN103520260B CN103520260B CN201310486945.4A CN201310486945A CN103520260B CN 103520260 B CN103520260 B CN 103520260B CN 201310486945 A CN201310486945 A CN 201310486945A CN 103520260 B CN103520260 B CN 103520260B
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- radix
- water
- ball
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 22
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 71
- 239000003814 drug Substances 0.000 claims abstract description 29
- 239000006071 cream Substances 0.000 claims abstract description 27
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 21
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 21
- 241000208340 Araliaceae Species 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 229930182490 saponin Natural products 0.000 claims abstract description 17
- 150000007949 saponins Chemical class 0.000 claims abstract description 17
- 235000017709 saponins Nutrition 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- 244000293323 Cosmos caudatus Species 0.000 claims abstract description 11
- 235000005956 Cosmos caudatus Nutrition 0.000 claims abstract description 11
- 244000153234 Hibiscus abelmoschus Species 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 229920002472 Starch Polymers 0.000 claims abstract description 5
- 235000019698 starch Nutrition 0.000 claims abstract description 5
- 239000008107 starch Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000006187 pill Substances 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000010828 elution Methods 0.000 claims description 16
- 229930003944 flavone Natural products 0.000 claims description 16
- 150000002213 flavones Chemical class 0.000 claims description 16
- 235000011949 flavones Nutrition 0.000 claims description 16
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Polymers C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 13
- 230000000274 adsorptive effect Effects 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000002481 ethanol extraction Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- 230000004087 circulation Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 230000035876 healing Effects 0.000 abstract description 3
- 238000000465 moulding Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 33
- 208000019622 heart disease Diseases 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 208000031225 myocardial ischemia Diseases 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000000556 factor analysis Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 241000630329 Scomberesox saurus saurus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310486945.4A CN103520260B (zh) | 2013-10-17 | 2013-10-17 | 一种治疗冠心病心绞痛的药物组合及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310486945.4A CN103520260B (zh) | 2013-10-17 | 2013-10-17 | 一种治疗冠心病心绞痛的药物组合及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103520260A CN103520260A (zh) | 2014-01-22 |
CN103520260B true CN103520260B (zh) | 2015-12-09 |
Family
ID=49922847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310486945.4A Expired - Fee Related CN103520260B (zh) | 2013-10-17 | 2013-10-17 | 一种治疗冠心病心绞痛的药物组合及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103520260B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114894915A (zh) * | 2022-03-31 | 2022-08-12 | 安徽中医药大学 | 一种救心丸指纹图谱的建立方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066191A (zh) * | 1992-05-20 | 1992-11-18 | 沈阳中药厂 | 救心金丹的制取工艺 |
CN101342208A (zh) * | 2008-08-22 | 2009-01-14 | 广东宏兴集团股份有限公司宏兴制药厂 | 一种治疗冠心病、心绞痛、心律失常的中药组合物及其制备方法 |
CN101342207A (zh) * | 2008-08-22 | 2009-01-14 | 广东宏兴集团股份有限公司宏兴制药厂 | 一种治疗冠心病、心绞痛、心律失常、高血脂的中药组合物及其制备方法 |
-
2013
- 2013-10-17 CN CN201310486945.4A patent/CN103520260B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066191A (zh) * | 1992-05-20 | 1992-11-18 | 沈阳中药厂 | 救心金丹的制取工艺 |
CN101342208A (zh) * | 2008-08-22 | 2009-01-14 | 广东宏兴集团股份有限公司宏兴制药厂 | 一种治疗冠心病、心绞痛、心律失常的中药组合物及其制备方法 |
CN101342207A (zh) * | 2008-08-22 | 2009-01-14 | 广东宏兴集团股份有限公司宏兴制药厂 | 一种治疗冠心病、心绞痛、心律失常、高血脂的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103520260A (zh) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112972547A (zh) | 一种治疗气血两虚症候的中药组合物及其制备方法和应用 | |
CN102349963A (zh) | 一种预防微血栓形成的保健品及其制备方法 | |
WO2004096249A1 (fr) | Composition contenant radix codonopsis pilosulae et radix astragali et hedysari, sa methode de production et d'utilisation | |
CN109106760A (zh) | 肉苁蓉苯乙醇苷改善睡眠的新用途及其应用 | |
CN103520260B (zh) | 一种治疗冠心病心绞痛的药物组合及制备方法 | |
CN101897770B (zh) | 一种骨刺胶囊及其制备工艺 | |
CN103479754A (zh) | 降压药及其制备方法 | |
CN102068520B (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN100484563C (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN104161798B (zh) | 一种复方丹参提取物及其应用 | |
CN102784230B (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN101697989B (zh) | 三七及其提取物在制备治疗和/或预防冠状动脉粥样硬化药物的用途 | |
CN104740054B (zh) | 一种防治心肌缺血的药物组合物及其制备方法和用途 | |
CN104257839B (zh) | 一种具有降糖降脂保护血管内皮作用的中药组合物及其制备方法 | |
CN103083429A (zh) | 降血脂中药组方 | |
CN103372138B (zh) | 一种含有生脉饮有效成分的药物组合物及其制备方法 | |
CN101623325B (zh) | 芳香新塔花总黄酮提取物及其生产方法和心血管药物的应用 | |
CN1325509C (zh) | 西洋参果总皂苷提取物在制备药物中的用途 | |
CN101129431A (zh) | 一种防治心脑血管疾病及相关疾病的中药组合物及其制备方法和其应用 | |
CN110664826A (zh) | 一种麦冬皂苷d’制剂及其降血糖药物新用途 | |
CN110664828A (zh) | 一种麦冬皂苷d制剂及其降血糖药物新用途 | |
CN103798475B (zh) | 改善围绝经期亚健康状态的中草药蜜茶(无糖颗粒)及制备工艺 | |
CN108836997A (zh) | 一种用于癌症康复治疗的药物及制备方法 | |
CN108478701A (zh) | 一种增强免疫力的含片 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Shouxu Inventor after: Hao Xueyan Inventor after: Zheng Jiafu Inventor after: Peng Xiuzhong Inventor after: Zhao Bing Inventor after: Wang Xiaobin Inventor after: Xu Quanli Inventor after: Yang Yiping Inventor after: He Jian Inventor after: Jing Jianfang Inventor before: Li Hongliang Inventor before: Jing Wenguang Inventor before: Wang Shouxu Inventor before: Zheng Jiafu Inventor before: Zhao Bing Inventor before: Zeng Yan Inventor before: Sun Shouguo Inventor before: Song Xinghua Inventor before: Peng Xiuzhong Inventor before: Yang Yiping |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151105 Address after: 236800 No. 23, Lixin Road, Qiaocheng District, Anhui, Bozhou Applicant after: HUATUO MEDICINES CO., LTD. Address before: 236800 Anhui Hua Tuo National Medicine Co., Ltd. 23 Lixin Road, Qiaocheng District, Anhui, Bozhou Applicant before: Li Hongliang |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind for the treatment of coronary heart disease and angina pectoris combination and preparation method for the treatment of Effective date of registration: 20161206 Granted publication date: 20151209 Pledgee: Agricultural Bank China Limited by Share Ltd Bozhou Qiaocheng branch Pledgor: HUATUO MEDICINES CO., LTD. Registration number: 2016990001068 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180807 Granted publication date: 20151209 Pledgee: Agricultural Bank China Limited by Share Ltd Bozhou Qiaocheng branch Pledgor: HUATUO MEDICINES CO., LTD. Registration number: 2016990001068 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition for treating coronary heart disease and angina and preparation method thereof Effective date of registration: 20180925 Granted publication date: 20151209 Pledgee: Agricultural Bank of China Limited by Share Ltd Bozhou Qiaocheng sub branch Pledgor: HUATUO MEDICINES CO., LTD. Registration number: 2018340000511 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151209 Termination date: 20181017 |
|
CF01 | Termination of patent right due to non-payment of annual fee |